comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 12:32:14 - browse：9

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The 10 drugs up first for Medicare price negotiation

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

Humana sues Biden admin over Medicare Advantage audit rule

Listen: Biogen's potential pivot, & Illumina's next chapter

What do new weight loss drugs mean for bariatric surgery?

Advances in CAR

A new House health package & hospitals’ new site

hotspot

comprehensive

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What drug price negotiations mean for Medicare Part D

Moonlake's readout produced a cash windfall. Risks remain

Feds fine Medicare Advantage plans for overcharging members

Bright Health sells Medicare Advantage business to Molina

A rare thyroid diagnosis led to unexpected, all

Drug repurposing or repositioning? The language matters

Why Novartis is changing the name of its research labs

After affirmative action ruling, medical educators look to 'holistic review'

Diversity in medical illustrations gets boost from Chidiebere Ibe

hotspot

NIH nominee Bertagnolli will get October confirmation hearing

Feds fine Medicare Advantage plans for overcharging members

Departing Stanford president retracts two papers

What drug price negotiations mean for Medicare Part D

Appeals court upholds limits to abortion pill

ALS advocates say criticism of new drugs misses bigger picture

focus

Wikipedia

Wikipedia

hotspot